Sobi Receives European Commission Approval for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

The European Commission has approved Aspaveli (pegcetacoplan) for adults and adolescents (12–17) with C3 glomerulopathy (C3G) or primary IC‑MPGN, marking the first approved therapy for primary IC‑MPGN and for adolescents in these indications in the EU. The approval, based on positive Phase 3 VALIANT data (n=124) showing reduced proteinuria, stabilized eGFR and clearance of C3 deposits (NEJM publication), addresses an estimated ~8,000 patients in Europe and follows Sobi’s (STO:SOBI) global co-development with Apellis; Sobi reported SEK 26 billion revenue in 2024. For investors, the decision is a positive commercial catalyst for Sobi’s rare-disease franchise but likely limited near-term revenue impact given the small patient population and label constraints.

Analysis

Market structure: EC approval materially derisks European commercialisation for Sobi (ex-U.S. rights) and validates Apellis’ (APLS) global programme; direct winners are Sobi (STO:SOBI) and Apellis via incremental revenues in a combined EU/US addressable base of ~13k patients. Orphan pricing power should be strong initially (list-price analogues €150k–€300k/pt/yr), so short-term margin accretion for Sobi is realistic, but absolute top-line is limited (EU peak-revenue order €200m–€800m depending on uptake). Payers and HTA bodies are the key chokepoints controlling realised pricing and volumes.

Risk assessment: Tail risks include adverse national reimbursement rulings (price cuts >30%), unexpected safety signals in broader real-world use, or manufacturing/CMC supply disruptions; any of these could halve revenue potential. Near-term market reaction (days–weeks) will be sentiment-driven; medium-term (3–12 months) hinge on first national reimbursement decisions and rollout logistics; long-term (2–5 years) depends on durable efficacy, label expansion, and competition from other complement modulators.

Trade implications: Tactical longs on Sobi (ex-EU commercial upside) and structured bullish exposure to Apellis (U.S. commercial rights) are sensible; implied volatility should fall after approval so prefer call spreads to limit premium. Consider small hedges vs dialysis operators (FMS/DVA) where lost progression-to-dialysis volume could be a multi-year headwind but is modest vs their revenue base. Key catalysts to trade around: national HTA outcomes in Germany/France/UK (next 3–6 months), early commercial uptake metrics (first 6–12 months), and any safety/CMC updates.

Contrarian angles: Consensus overlooks payer resistance — even with NEJM data, 8–10k patient pools mean payers can demand steep discounts or restrictive criteria; uptake may be 10%–30% initially, not 50%+. Also administration frequency (twice-weekly) and required concomitant RAS therapy reduce eligible population. If reimbursement is tight, Sobi could underdeliver relative to headline enthusiasm while Apellis (U.S. pricing power) may capture disproportionate upside.

Key Decisions for Investors

• Establish a 2–3% long position in Sobi (STO:SOBI) within the next 2 weeks to capture European launch; set a 12-month target of +20–30% and a hard stop-loss at -15% (trim to 50% if any major EU HTA mandates >30% price cut).
• Allocate 1% portfolio to a 6-month Apellis (APLS) call spread (buy 1x ~30% OTM call, sell 1x ~60% OTM call) to play U.S. commercial upside with capped premium exposure; reassess after Q2–Q3 commercial updates or 90 days after U.S. launch metrics are published.
• Implement a pair hedge: long Sobi 2% vs short Fresenius Medical Care (FMS) 1% to offset small but real dialysis-volume downside risk; rebalance after 6 months based on first 3 national reimbursement decisions.
• Trigger rule: if within 90 days any major EU market (DE/FR/UK) limits reimbursement to <30% of labelled population or forces >30% discount from list, reduce Sobi exposure by 50% and rotate proceeds into APLS calls and cash.